Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

The invention relates to derivatives of apramycin-based aminoglycoside antibacterial drugs modified in positions C5 and/or C6 and O5 and/or O6. The modifications impart favourable properties regarding increased selectivity and retention of activity in the presence of resistance determinants of the AAC(3) class. The invention further relates to said compounds for use in the therapy of bacterial infection by systemic administration, especially in instances where the infection is caused by a pathogen comprising a resistance determinant of the AAC(3) class, in particular AAC(3)-IV.

The invention relates to derivatives of apramycin-based aminoglycoside antibacterial drugs modified in positions C5 and/or C6 and O5 and/or O6. The modifications impart favourable properties regarding increased selectivity and retention of activity in the presence of resistance determinants of the AAC(3) class. The invention further relates to said compounds for use in the therapy of bacterial infection by systemic administration, especially in instances where the infection is caused by a pathogen comprising a resistance determinant of the AAC(3) class, in particular AAC(3)-IV.

The present invention relates to a method of producing a chitin oligomer, including subjecting chitin-containing biomass to partial hydrolysis while pulverizing the chitin-containing biomass with a pulverization apparatus in the co-presence of water and an acid catalyst selected from phosphoric acid, nitrous acid, and an organic acid (Method 1); a method of producing N-acetylglucosamine, including hydrolyzing a chitin oligomer obtained by the Method 1 by adding water thereto, followed by heating (Method 2); and a method of producing a 1-O-alkyl-N-acetylglucosamine, including alcoholyzing a chitin oligomer by adding an alcohol thereto (Method 3).

The present invention relates to a method of producing a chitin oligomer, including subjecting chitin-containing biomass to partial hydrolysis while pulverizing the chitin-containing biomass with a pulverization apparatus in the co-presence of water and an acid catalyst selected from phosphoric acid, nitrous acid, and an organic acid (Method 1); a method of producing N-acetylglucosamine, including hydrolyzing a chitin oligomer obtained by the Method 1 by adding water thereto, followed by heating (Method 2); and a method of producing a 1-O-alkyl-N-acetylglucosamine, including alcoholyzing a chitin oligomer by adding an alcohol thereto (Method 3).

The present disclosure relates generally to fluorinated glucosamine analogs and uses thereof, including analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, such as multiple sclerosis; inflammation; cancer; central nervous system injury; or conditions associated with up-regulation of an extracellular matrix, such as chondroitin sulfate proteoglycans.

The present disclosure relates generally to fluorinated glucosamine analogs and uses thereof, including analogs of N-acetyl glucosamine fluorinated at 4- and/or 6-position(s) and derivatives of xylose at anomeric position for the treatment of a neurological disease, such as multiple sclerosis; inflammation; cancer; central nervous system injury; or conditions associated with up-regulation of an extracellular matrix, such as chondroitin sulfate proteoglycans.

Described herein are oral care compositions comprising a deoxy sugar antimetabolite and methods of inhibiting microbial biofilm formation and/or degrading a microbial biofilm in a subject.

Described herein are oral care compositions comprising a deoxy sugar antimetabolite and methods of inhibiting microbial biofilm formation and/or degrading a microbial biofilm in a subject.

There is disclosed herein compositions, methods, uses and systems for reducing pain in a patient that emanates from a body area, preferably spine or joint. Methods of treatment or prevention are described for a disease or condition selected from degenerative disc disease, disc injury, pain, arthritis, or suspected arthritis.